[Edaily Reporter KIM JI-WAN ] curacle co., ltd.(365270)is moving forward with a U.S. Phase 2b clinical trial to develop an oral treatment for diabetic macular edema (DME). The trial will re-evaluate the treatment’s efficacy in patients with low vision, who showed relatively significant improvements in visual acuity in previous clinical trials. The goal is to confirm the potential of an oral treatment as an alternative to repeated intravitreal injections.
curacle co., ltd. Demonstrates Efficacy of ‘CU01’ for Diabetic Nephropathy in Phase 2b Trial… Announces Topline Results
curacle co., ltd. announced on the 20th that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2b clinical trial of CU06 (active ingredient: rivastret), an oral candidate drug for retinal diseases.
CU06 is a new drug candidate with a mechanism of action that inhibits dysfunction in vascular endothelial cells. It is being developed to restore damaged blood vessel barriers and protect retinal neurons, thereby preventing or improving vision loss.
Diabetic macular edema is a condition in which fluid accumulates in the macula due to damage to the retinal blood vessels caused by diabetes, leading to vision loss. Currently, the primary treatment involves injecting drugs that inhibit vascular endothelial growth factor (VEGF) directly into the eye. However, this approach has limitations, as it requires long-term, repeated administration and places a significant burden on patients in terms of pain and the need for frequent hospital visits.
Curacle co., ltd. previously conducted a Phase 2a clinical trial involving 67 patients at 11 clinical sites in the United States. Among patients who completed the trial according to the protocol, those in a subgroup with best-corrected visual acuity (BCVA) of 69 letters or less prior to treatment showed an average improvement of approximately 6 letters in visual acuity 12 weeks after receiving a 300 mg dose of CU06.
Based on these subgroup analysis results, the patient selection criteria for this Phase 2b clinical trial were refined. The trial will enroll 156 patients with central macular edema and best-corrected visual acuity (BCVA) ranging from 25 to 69 letters on the ETDRS chart.
Participants will be randomly assigned to groups receiving 200 mg or 300 mg of CU06 or a placebo. They will take the medication once daily for 24 weeks, and efficacy will be evaluated by comparing the change in best-corrected visual acuity between baseline and week 24. This will confirm the statistical significance of the visual acuity improvement and determine the optimal dose for the Phase 3 clinical trial.
According to U.S. clinical trial registration information, this trial is scheduled to begin in December 2026 and conclude its primary evaluation in January 2028. However, this schedule is tentative and may vary depending on actual patient recruitment and the progress of the trial.
Last year, curacle co., ltd. held a Type C meeting with the FDA to discuss the direction of subsequent clinical development. The clinical trial will be managed by Syneos Health, a global contract research organization (CRO) with expertise in ophthalmology.
A curacle co., ltd. spokesperson stated, “Through this trial, we plan to more thoroughly verify the visual acuity improvements and safety observed in the Phase 2a trial and determine the appropriate dosage for the Phase 3 trial,” adding, “We will do our utmost to provide a new treatment option—an oral medication—for patients who find repeated intraocular injections burdensome.”
Park Ji-hyun, Director of the Digital Society Planning Division at the Ministry of Science and ICT, stated during a panel discussion at the “Seminar on Building a Win-Win, Collaborative K-Blockchain E…
curacle co., ltd.(365270)is moving forward with a U.S. Phase 2b clinical trial to develop an oral treatment for diabetic macular edema (DME). The trial will re-evaluate the treatment’s efficacy in pat…
#Aimed Bio Inc.’s antibody-drug conjugate (ADC) “BHV-1530 (AMB302),” which was licensed to U.S.-based Biohaven, has demonstrated initial anticancer efficacy in a Phase 1 clinical trial. Biohaven plans…